Bevacizumab is a vascular endothelial growth factor-A-specific angiogenesis inhibitor
indicated as an adjunct to chemotherapy for the treatment of several types of cancer …

With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the
array of toxicities associated with these agents be well-recognized and managed, especially …

Cancer is considered one of the leading causes of mortality worldwide. At the same time,
hypertension is recognized as one of the most common comorbidities in cancer patients …

As targeted drug therapy is increasingly applied in the treatment of colon cancer,
understanding and managing the adverse reactions of patients is becoming increasingly …

Purpose Current neoadjuvant chemoradiotherapy had limited impact on distal metastasis
and survival in locally advanced rectal cancer. Here, we investigated a new sandwich-like …

血管内皮生长因子(VEGF) 信号轴在建立和维持肾小球滤过屏障中发挥不可或缺的作用.
蛋白尿是VEGF 信号通路抑制剂的常见不良反应之一, 该类药物可引起肾小球足细胞和肾小球 …

Purpose Vascular endothelial growth factor (VEGF) inhibitors are widely used in
chemotherapy for non-small lung cancer (NSCLC). The purpose of the current study was to …

Background and objective: Bevacizumab (BVZ) is a recombinant humanized antibody that
inhibits the vascular endothelial growth factor A (VEGFA) and is used for the treatment of …

[目的] 探讨贝伐珠单抗对结直肠癌细胞血管内皮生长因子(VEGF) 相关受体的影响.[方法] RT-
PCR, Western blotting 检测不同浓度贝伐珠单抗对结直肠癌肿瘤细胞VEGF …

The objective of this study was to investigate whether improving glycemic control reduces
the prevalence and progression of proteinuria among bevacizumab (BEV)-treated cancer …